Biohaven is a clinical-stage biopharmaceutical company developing therapies for neurological, neuropsychiatric, immunological, and rare diseases.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Bridgewater | 55 | New buy | 100,249 | $1,338,324 | 0.0% |
| Paul Tudor Jones / Tudor | 61 | Trimmed -31% | 63,606 | $849,140 | 0.0% |
| Filed | Insider | Role | Shares | Value | |
|---|---|---|---|---|---|
| 2026-03-09 | CHILDS JOHN W | director | 28,400 | $864,212 | Form 4 |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.